Tandutinib

also known as MLN518 · CT53518 · Mln-0518 · NSC-759851

Small molecule targets FLT3, KIT, PDGFRB via inhibition

Developed for: acute myeloid leukemia · gliosarcoma · adult glioblastoma · anaplastic astrocytoma · anaplastic oligoastrocytoma · anaplastic oligodendroglioma · clear cell renal carcinoma · glioblastoma
+4 more
· metastatic malignant neoplasm · myelodysplastic syndrome · prostate cancer · brain neoplasm
Investigated by: Millennium Pharmaceuticals, Inc. · National Cancer Institute (NCI)

Trials 8

today NCT00904852 · Ph 1 NCT00667394 · Ph 2 NCT00379080 · Ph 1/2 NCT00408902 · Ph 2 NCT00390468 · Ph 2 NCT00274248 · Ph 1 NCT00064584 · Ph 1

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT00904852	Jun 2009 → May 2010	glioblastoma	Millennium Pharmaceuticals, Inc.	Withdrawn	No outcome recorded
Phase 1	NCT00274248	Mar 2005 → May 2007	acute myeloid leukemia	Millennium Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT00064584	May 2002 → Jan 2005	acute myeloid leukemia, myelodysplastic syndrome	Millennium Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT00379080	Jan 2007 → Sep 2012	adult glioblastoma, giant cell glioblastoma, gliosarcoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT00297921	—	acute myeloid leukemia	Millennium Pharmaceuticals, Inc.	Withdrawn	No outcome recorded
Phase 23 trials
Phase 2	NCT00667394	Apr 2008 → Jul 2011	anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, gliosarcoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00408902	Nov 2006 → Oct 2008	clear cell renal carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00390468	Oct 2006 → Nov 2009	metastatic malignant neoplasm, prostate cancer	National Cancer Institute (NCI)	Completed	No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

Field	Value	Cited text
Known as	Tandutinib	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00667394 ↗ 5 NCT00379080 ↗ NCT00390468 ↗ NCT00408902 ↗ NCT00297921 ↗ NCT00904852 ↗
Known as	CT53518	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00064584 ↗
Known as	Mln-0518	ChEMBL registry synonym — accepted as the source's own label CHEMBL124660 ↗
Known as	MLN518	“A Phase 1, Multicenter, Open-Label, Dose Escalation Study of Tandutinib (Formerly MLN518) in Combination With Temozolomide and Bevacizumab Following Concurrent Radiation...” NCT00904852 ↗ 3 “Tandutinib (MLN518) along with bevacizumab represents an attempt to further capitalize on the concept of targeting the tumor vasculature.” NCT00667394 ↗ “Tandutinib (MLN518) previously known as CT53518.” NCT00390468 ↗ NCT00274248 ↗
Known as	NSC-759851	ChEMBL registry synonym — accepted as the source's own label CHEMBL124660 ↗
Action	Inhibit	“Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT00379080 ↗ 2 “Platelet-derived growth factor receptor beta inhibitor” CHEMBL124660 ↗ “Stem cell growth factor receptor inhibitor” CHEMBL124660 ↗
Modality	Small molecule	“a small-molecule inhibitor of the type III receptor tyrosine kinases” NCT00390468 ↗
Route	Oral	“an oral 28-day course of CT53518” NCT00064584 ↗
Target	FLT3	“Tandutinib is a small molecule inhibitor of fms-like tyrosine kinase receptor-3 (FLT3), platelet derived growth factor receptor (PDGFR), and cKIT (type III receptor tyrosine kinases).” NCT00667394 ↗
Target	KIT	“Stem cell growth factor receptor inhibitor” CHEMBL124660 ↗
Target	PDGFRB	“Platelet-derived growth factor receptor beta inhibitor” CHEMBL124660 ↗